Research news
Duchenne muscular dystrophy:
- 19 April 2012
AVI Biopharma release new results from phase 2b exon skipping trial AVI Biopharma has announced preliminary results of their phase 2b study of Eteplirsen for Duchenne muscular dystrophy. - 5 April 2012
New drug a potential treatment for Duchenne muscular dystrophy Scientists have shown that increasing the amount of a protein called heat shock protein 72 can have a beneficial effect in a mouse model of Duchenne muscular dystrophy. - 14 March 2012
Update on BIO-NMD: A research project looking into Duchenne, Becker, Ullrich and Bethlem muscular dystrophies An update on the progress of BIO-NMD - an EU funded project searching for biomarkers - 14 February 2012
Clinical trial plans announced for utrophin drug for Duchenne Summit has outlined plans to test a drug for Duchenne and Becker muscular dystrophies - a phase 1 trial will start soon and results should be available before the end of this year. - 13 February 2012
Update on ataluren extension trial for Duchenne PTC Therapeutics expects that most study centres involved in the ataluren extension trial in the UK, continental Europe, Israel and Australia will open between March and June this year. - 19 December 2011
Summit secures funding for utrophin drug for Duchenne Summit plc has secured £1 million worth of funding from several US-based charities to manufacture a new formulation of a potential drug for Duchenne and Becker muscular dystrophies and conduct a Phase 1 clinical trial. - 30 November 2011
Ataluren extension trial for Duchenne about to start PTC Therapeutics has affirmed their commitment to develop ataluren to treat boys with Duchenne muscular dystrophy and announced progress in starting an extension trial in the UK, Europe, Israel and Australia. - 23 November 2011
Reliable muscle function test for boys with Duchenne developed The Muscular Dystrophy Campaign's North Star project has developed a way to reliably test the muscle function of boys with Duchenne muscular dystrophy. - 16 November 2011
Combining two exon skipping drugs to treat Duchenne muscular dystrophy A recent scientific publication shows that it may be possible to combine different “exon-skipping” molecular patches into an effective treatment package for Duchenne muscular dystrophy. - 15 November 2011
AVI Biopharma collaborates to develop new exon skipping drugs for Duchenne AVI Biopharma has entered into collaborations with various research institutions and funding bodies in the US to develop two new exon skipping drugs for Duchenne muscular dystrophy.
